Methods of treating neurological conditions with hematopoeitic growth factors

Abstract

The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

1 . A method of treating a neurological condition in a mammal, comprising administering to the mammal in need thereof, a hematopoietic factor selected from the group consisting of IL-5, a derivative thereof, a mimetic thereof, and a combination thereof in an amount sufficient to treat the neurological condition. 
     
     
         2 . The method of  claim 1 , wherein said neurological condition is selected from the group consisting of a neurological disease with pathophysiological mechanisms involving ischemia, a neurological disease with pathophysiological mechanisms involving hypoxia, a neurodegenerative disease, and a disease of the nervous system accompanied by neural cell death. 
     
     
         3 . The method of  claim 1 , wherein the neurological condition is neurological disease with pathophysiological mechanisms involving ischemia or hypoxia. 
     
     
         4 . The method of  claim 3 , wherein the neurological disease with pathophysiological mechanisms involving ischemia or hypoxia is stroke. 
     
     
         5 . The method of  claim 1 , further comprising administering one or more additional hematopoietic factors. 
     
     
         6 . The method of  claim 1 , wherein the neurological condition is a psychiatric condition. 
     
     
         7 . The method of  claim 6 , wherein the psychiatric condition is depression. 
     
     
         8 . The method of  claim 1 , wherein the neurological condition is a dementia or multiple sclerosis. 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . The method of  claim 1 , wherein the neurological condition is stroke, Parkinson's disease, amyotrophic lateral sclerosis, neurotrauma, cerebral ischemia due to cardiac arrest, cerebral ischemia during an operative procedure, multiple sclerosis, Huntington's disease, glaucoma, neuropathy, a lysosomal storage disease, or spinal cord injury. 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . The method of  claim 1 , which further comprises administering a hemodynamically active compound. 
     
     
         15 . The method of  claim 1 , which further comprises administering tissue plasminogen activator to the mammal. 
     
     
         16 . The method of  claim 1 , which further comprises administering an agent that facilitates passage over the blood brain barrier. 
     
     
         17 . The method of  claim 1 , which further comprises administering an anti-apoptotic agent. 
     
     
         18 . The method of  claim 15 , wherein the neurological condition is stroke. 
     
     
         19 . The method of  claim 10 , further comprising administering tissue plasminogen activator to the mammal. 
     
     
         20 . The method of  claim 1 , wherein the hematopoietic factor is a human factor or derived from a human factor. 
     
     
         21 . The method of  claim 1 , wherein the mammal is human. 
     
     
         22 . The method of  claim 1 , wherein the hematopoietic factor is administered by one or more modes of administration selected from the group consisting of direct intracerebral injection, intravenously, intraarterially, orally, and subcutaneously. 
     
     
         23 - 55 . (canceled) 
     
     
         56 . A method for enhancing the cognitive ability of a mammal in need thereof, comprising administering a hematopoietic factor selected from the group consisting of IL-3, IL-5, a derivative thereof, a mimetic thereof, and a combination thereof in an amount sufficient to enhance the cognitive ability of a mammal relative to the mammal prior to the administrating. 
     
     
         57 . The method of  claim 56 , wherein the mammal is a human.